Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 07/22 10:00:13 pm
125.03 USD   -0.10%
07/23 JOHNSON & JOHNS : subsidiary pays $18 million to U.S. in settlement
07/22DJJOHNSON & JOHNS : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNS : Acclarent Unit in $18 Million U.S. Settlement
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/23 JOHNSON & JOHNSON : subsidiary pays $18 million to U.S. in settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/21 JOHNSON & JOHNSON : DePuy Synthes Announces Agreement with Materialise for 3D-Pr..
07/21 JOHNSON & JOHNSON : tops 2Q forecasts despite profit drop
07/21 Unilever sharpens P&G rivalry by buying Dollar Shave Club
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20 JOHNSON & JOHNSON : J&J rises on Wall St. beat, lifts forecast
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20 JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2016
More news
Sector news : Pharmaceuticals - NEC
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook--Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 6 MONTH PORTFOLIO UPDATE : Good News, Double-Digit Increase In Both Income And V..
07/22 DOMINION RESOURCES INC. : An Income Utility Company For The Future But At A Rich..
07/22 JOHNSON & JOHNSON : 3 Reasons To Be Optimistic From The Q2 Results
07/22 Healthcare ratings - upgrades/downgrades
07/21 UNILEVER AND DOLLAR SHAVE CLUB : Delivering A Close, Uncomfortable Shave For Pro..
Advertisement
Financials ($)
Sales 2016 72 055 M
EBIT 2016 21 649 M
Net income 2016 16 531 M
Finance 2016 14 348 M
Yield 2016 2,51%
P/E ratio 2016 21,23
P/E ratio 2017 18,84
EV / Sales 2016 4,57x
EV / Sales 2017 4,29x
Capitalization 343 913 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 0,40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
BRISTOL-MYERS SQUIBB C..10.02%126 333
More Results